COVID-19 Vaccine Efficacy in Immunocompromised Children

Strategic Insights -

Researchers at the Institute for Cancer Research and Treatment (IRCCS) in Rome, Italy, conducted a pilot prospective study to evaluate the impact of cancer treatment and stem cell transplantation on immunogenicity of two doses of the BNT162b2 vaccine in pediatric patients. The study involved 35 children aged 5-12 years who were receiving cancer treatment and 12 healthy donors. The researchers found that the seroconversion rate after two vaccine doses was 79.3%, with significant variability among the different groups of patients. The study also revealed that the combination of antibodies, memory B cells, and specific T-cell responses was a reliable indicator of vaccine immune efficacy in frail patients.

Key Takeaways:

  • The BNT162b2 vaccine showed a seroconversion rate of 79.3% in immunocompromised children after two doses, with variability among different patient groups.
  • The study found that the combination of antibodies, memory B cells, and specific T-cell responses was a reliable indicator of vaccine immune efficacy in frail patients.
  • The Hematopoietic Stem Cell Transplantation (HSCT) subgroup showed the best immune function, with 80% complete response and optimal T-cell function.
  • The study revealed that 11.1% of patients with hematological malignancies (HM) and 27.3% of patients with solid tumors (ST) had no B- and T-cell memory, despite being able to produce antibodies.
  • The researchers observed that the specific T-cell response was observed in most patients with solid tumors (81.8%) and HSCT recipients (85.7%) but at a lesser extent in those with hematological malignancies (55.5%).

Statistics:

  • 79.3% seroconversion rate after two vaccine doses in immunocompromised children
  • 80% complete immune response in the HSCT subgroup
  • 85.7% patients with HSCT showed specific T-cell response
  • 81.8% patients with solid tumors showed specific T-cell response
  • 55.5% patients with hematological malignancies showed specific T-cell response
  • 11.1% HM patients had no B- and T-cell memory
  • 27.3% ST patients had no B- and T-cell memory

Sources:

  • Heliyon. "Humoral and cellular immune response after mRNA SARS-CoV-2 vaccine in children on treatment for cancer: A pilot observational study." 2024,10(14):e34503. (Elsevier - http://www.heliyon.com)
  • NewsRx. "New COVID-19 Research from Institute for Cancer Research and Treatment (IRCCS) Outlined (Humoral and cellular immune response after mRNA SARS-CoV-2 vaccine in children on treatment for cancer: A pilot observational study)." Cancer Vaccine Week. July 29, 2024; p 157.